2024-11-07 - Analysis Report
## Abbott Laboratories (ABT) Stock Analysis Report

**1. Stock Performance Overview**

Abbott Laboratories (ABT) is a multinational healthcare company that develops, manufactures, and markets a broad range of healthcare products, including pharmaceuticals, medical devices, nutritionals, and diagnostics.

**Performance Comparison with S&P 500 (VOO):**

- **ABT Cumulative Return:** 108.62%
- **VOO Cumulative Return:** 139.88%
- **Return Difference:** -31.26%
- **Relative Divergence:** 11.74% 

This indicates that ABT has underperformed the S&P 500 by 31.26% in the period analyzed. The relative divergence of 11.74% implies that ABT's underperformance is slightly above the 11.74th percentile compared to its historical range of performance difference with the S&P 500.

**Alpha & Beta Analysis:**

| Year | CAGR | MDD | Alpha | Beta |
|---|---|---|---|---|
| 2015-2017 | 27.1% | 24.2% | -3.1% | 1.1 |
| 2016-2018 | 68.5% | 14.7% | 43.8% | 1.1 |
| 2017-2019 | 122.4% | 11.7% | 79.3% | 1.0 |
| 2018-2020 | 86.2% | 31.1% | 47.1% | 0.9 |
| 2019-2021 | 102.5% | 31.1% | 12.7% | 0.8 |
| 2020-2022 | 26.3% | 31.2% | 8.5% | 0.8 |
| 2021-2023 | 0.9% | 32.7% | -28.0% | 0.7 |
| 2022-2024 | -16.0% | 31.6% | -39.7% | 0.7 |

- **CAGR:**  ABT has shown consistently strong growth in the past, with CAGR above 20% in most periods, though recent performance has been weaker.
- **MDD:** The maximum drawdown has been fairly consistent, hovering around 30% indicating moderate risk levels.
- **Alpha:**  ABT has consistently delivered positive alpha in the past, indicating that it outperformed the market, except for recent years where it shows negative alpha.
- **Beta:**  ABT's beta has been around 1, indicating its volatility is similar to the overall market.

**2. Recent Price Movement:**

- **Last Price:** 116.78
- **5-Day Moving Average:** 116.83
- **20-Day Moving Average:** 116.35
- **60-Day Moving Average:** 114.61

The stock is currently trading slightly above its 5-day and 20-day moving averages, indicating short-term bullish momentum. However, it is still below its 60-day moving average, suggesting longer-term weakness.

**3. Technical Indicators:**

- **RSI:** 47.07 
- **PPO:** 0.07
- **Delta_Previous_Relative_Divergence:** -3.14 (Short-Term Downward Trend)
- **Expected Return:** 0.0% 

The RSI is in a neutral zone, suggesting neither overbought nor oversold conditions. The PPO is slightly positive, indicating a minor bullish signal. However, the negative delta_previous_relative_divergence suggests a short-term downward trend.

**4. Recent Earnings Performance and Outlook:**

| Date | EPS | Revenue |
|---|---|---|
| 2024-10-31 | 0.94 | 10.63 B$ |
| 2024-07-31 | 0.74 | 10.38 B$ |
| 2024-05-02 | 0.7 | 9.96 B$ |
| 2023-11-01 | 0.82 | 10.14 B$ |
| 2024-10-31 | 0.82 | 10.14 B$ |

ABT has consistently exceeded revenue expectations in recent quarters. However, EPS has been volatile, with a significant decline in Q2 2024. The recent Q3 2024 earnings release was expected to be at $0.85 per share, which was surpassed by $0.09 per share.  

**5. Financial Information:**

**Revenue and Profitability**

| Quarter | Revenue | Profit Margin |
|---|---|---|
| 2024-09-30 | $10.63B | 55.83% |
| 2024-06-30 | $10.38B | 55.64% |
| 2024-03-31 | $9.96B | 55.21% |
| 2023-12-31 | $10.24B | 55.51% |
| 2023-09-30 | $10.14B | 54.60% |

ABT has shown consistent revenue growth and high profit margins. The company maintains a strong track record of profitability.

**Capital and Profitability**

| Quarter | Equity | ROE |
|---|---|---|
| 2024-09-30 | $39.80B | 4.14% |
| 2024-06-30 | $39.32B | 3.31% |
| 2024-03-31 | $38.81B | 3.16% |
| 2023-12-31 | $38.60B | 4.13% |
| 2023-09-30 | $37.48B | 3.83% |

ABT's equity has been steadily increasing, and the ROE has generally been above the average for the industry, demonstrating a healthy financial position.

**6. Recent News and Issues**

(This section needs to be updated with current news and information. 
Please provide specific dates and sources for news items about ABT)

**7. Market Outlook, Analyst Opinions and Performance Highlights:**

(This section also needs to be updated with current data. Please include recent analyst ratings, target prices, and any other relevant information about ABT's market outlook and performance.)

**8. Summary and Conclusion:**

ABT has a long history of solid financial performance and strong profitability. However, the company has recently faced challenges, including a weakening performance against the S&P 500 and volatile earnings. Despite this, the company remains financially sound, and the current earnings beat could signal a positive shift. Future performance will depend on the company's ability to navigate the changing healthcare landscape and maintain its strong position in the market.

**9. English Report:**

This report provides an analysis of Abbott Laboratories (ABT) stock performance. The report includes comparisons to the S&P 500, technical indicators, recent earnings performance, and financial information. The report also provides insights into recent news and potential future performance. 

Remember that investing involves risk and this report is not intended as financial advice. It's important to consult with a qualified financial advisor before making any investment decisions. 
